Kimia Biosciences Peer Comparison

BSE: 530313

₹34.62

₹0.14 (0.41%)

As on 13-Oct-2026IST

Market cap

₹164 Cr

Revenue (TTM)

₹112 Cr

P/E Ratio

22.8

P/B Ratio

9.1

Div. Yield

0 %

Edit

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	164	19,042	17,941	18,554	15,956
Revenue (₹ Cr)	112	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	7.19	273.51	678.07	735.15	666.92
Net Margin (%)	6.37	16.19	28.10	26.88	20.60
RoE (%)	49.04	11.15	19.73	19.16	18.75
Price to Earnings	22.80	64.05	26.96	25.24	24.78
Price-To-Book	9.06	7.09	4.88	4.21	3.96

Income Statement (₹ Cr)

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	112.02	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	112.88	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	97.94	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	14.09	478.55	796.58	941.63	1,139.61
Depreciation	4.09	126.01	78.10	57.58	281.06
EBIT	10.00	352.55	718.48	884.05	858.55
Interest	2.60	52.11	0.88	7.69	190.64
Other Income	0.86	7.37	125.96	165.62	7.45
Exceptional Items	0.00	12.16	0.00	-49.16	-17.24
Profit before Tax	8.26	319.96	843.56	992.82	658.12
Provision for Tax	1.07	46.45	165.49	257.67	-8.80
Profit after Tax	7.19	273.51	678.07	735.15	666.92

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	17.72	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	24.29	266.35	28.74	91.50	1,392.75
Current Liabilities	61.18	848.06	385.94	627.48	2,077.10
Total Liabilities	111.21	3,310.68	3,207.85	4,911.11	6,865.52

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	37.97	2,525.44	1,291.22	770.28	5,617.77
Current Assets	63.62	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	111.21	3,310.68	3,207.85	4,911.11	6,865.52
Total Debt*	32.57	586.37	0.55	2.50	2,421.66
Net Current Assets	2.44	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	0.12	76.22	0.64	363.79	51.96

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	21.31	132.27	432.37	659.75	1,065.01
Cash Flow from Investing Activities	-4.70	-199.13	-334.73	-71.34	-79.97
Cash from Financing Activities	-16.55	62.65	-38.32	-205.34	-881.32
Net Cash Inflow / Outflow	0.06	-4.21	59.32	383.07	103.72

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	42.18	6.95	26.22	26.21	13.59
ROE (%)	49.04	11.15	19.73	19.16	18.75
ROA (%)	13.92	7.80	18.69	14.95	9.26
EBIT Margin (%)	8.93	20.95	31.41	34.40	26.58
Net Margin (%)	6.37	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	-6.73	27.91	15.01	10.69	9.59
EBIT Growth (%)	-36.11	58.32	18.45	24.14	16.84
Net Profit Growth (%)	-18.17	149.56	19.61	-9.09	62.68
EPS Growth (%)	-18.17	-3.57	17.73	14.40	67.41
Book Value Growth (%)	2,910.91	30.63	23.77	17.30	10.19

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	22.80	67.94	26.96	24.05	24.15
Price / Book Value	9.06	7.09	4.88	4.21	3.96
Dividend Yield (%)	0.00	0.06	0.34	1.85	0.00
EV/EBITDA	13.89	41.07	21.26	16.40	15.97
Market Cap (₹ Cr)	201.13	6,484.12	15,219.80	18,318.10	19,292.77

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	1.29	0.07	0.00	0.00	0.24
Short term debt to equity ratio	1.97	0.13	0.00	0.00	0.14
Current Ratio	1.04	1.31	6.70	6.06	0.74
Quick Ratio	0.61	0.88	5.59	5.31	0.53
Interest Coverage	4.18	7.14	959.59	130.11	4.45

	Kimia Biosciences	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	26.17	30.84	36.10	7.07	21.07
Asset Turnover	2.17	0.48	0.63	0.52	0.45
Receivable days	98.68	118.15	110.70	29.10	54.06
Inventory Days	100.34	98.29	65.86	69.53	32.16
Payable days	233.00	128.16	105.88	76.77	140.91
Cash Conversion Cycle	-33.97	88.28	70.68	21.86	-54.69

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.